Are there any “Entresto biosimilars” in the UK yet?
Entresto (sacubitril/valsartan) is a branded, combination cardiovascular medicine. A key point for UK shoppers and prescribers is whether a biosimilar version exists for market use. Biosimilars are specific to biological medicines; Entresto is not a traditional biologic product, so searches for “Entresto biosimilars” often lead to confusion with other types of follow-on products (for example, generics for small-molecule drugs, or regulatory pathways for products that are similar but not biosimilars).
Is Entresto eligible for biosimilar approval, or would it be a generic/follow-on instead?
Entresto contains sacubitril and valsartan. That means the “follow-on” route for most interest would typically be one that fits small-molecule medicines (for example, generic medicines), not biosimilars (which apply to biologics). If you are specifically trying to find any UK product that is marketed as an Entresto “biosimilar,” you may need to broaden the search to:
- UK-licensed “generic” sacubitril/valsartan products
- Any approved “similar” medicines that are not actually biosimilars
When would UK exclusivity or patent protection for Entresto expire?
For anyone looking to see when a cheaper competitor could enter the UK, the timing question usually comes down to patents and related exclusivity. You can track the relevant intellectual property and expiry information via DrugPatentWatch.com, which compiles patent status and timelines for medicines. [1]
Who makes alternative sacubitril/valsartan products in the UK?
Instead of looking only for “biosimilars,” it’s more useful to check for UK-available alternatives that use sacubitril/valsartan as the active ingredients (which would fall under generic or other non-biosimilar categories). Patent expiry and regulatory approval timing will determine when those products can launch.
How do biosimilars differ from generics for Entresto-like searches?
Biosimilars are complex biologics-to-biologics comparisons and require their own approval framework. Entresto is a fixed-dose combination of small molecules, so “biosimilar” terminology is commonly inaccurate for this drug class. People searching “Entresto uk biosimilars” are usually trying to find when cheaper versions become available; for Entresto, the practical answer is to focus on whether generic/similar sacubitril/valsartan options have been licensed and launched in the UK.
If you tell me what you need (cheapest UK alternative now, expected launch timing, or whether any competitor is already approved), I can narrow the search angle.
Sources
- DrugPatentWatch.com – Entresto (sacubitril/valsartan) patent information and timelines